1,035 results on '"Hou, Jinlin"'
Search Results
2. Serum ECM1 is a promising biomarker for staging and monitoring fibrosis in patients with chronic hepatitis B
3. Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design
4. Prospective appraisal of clinical diagnostic algorithms for hepatocellular carcinoma surveillance in Chinese patients with chronic hepatitis B infection
5. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma
6. Elevated expression of HIGD1A drives hepatocellular carcinoma progression by regulating polyamine metabolism through c-Myc–ODC1 nexus
7. Expert consensus on the diagnosis and treatment of end-stage liver disease complicated by infections
8. A spatiotemporal atlas of mouse liver homeostasis and regeneration
9. Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China
10. CXCR7 genetic variant predicts treatment response of pegylated-interferon α in HBeAg-positive chronic hepatitis B patients
11. Anti-HBc mirrors the activation of HBV-specific CD8+ T cell immune response and exhibits a direct effect on HBV control
12. Early warning of hepatocellular carcinoma in cirrhotic patients by three-phase CT-based deep learning radiomics model: a retrospective, multicentre, cohort study
13. Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma
14. CTLA4+CD4+CXCR5−FOXP3+ T cells associate with unfavorable outcome in patients with chronic HBV infection
15. Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma
16. Structure-Enhanced Graph Neural ODE Network for Temporal Link Prediction
17. Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies
18. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial
19. Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B
20. An intronic genetic variant of ZHX2 predicts response to pegylated interferon α therapy in HBeAg-positive chronic hepatitis B patients
21. aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients
22. Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
23. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures
24. Alcohol induces intrahepatic humoral immunity-related suppression and delays the clearance of HBV infection
25. Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis
26. Interferon α facilitates anti-HBV cellular immune response in a B cell-dependent manner
27. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy
28. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis
29. Targeting cIAPs attenuates CCl4-induced liver fibrosis by increasing MMP9 expression derived from neutrophils
30. An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression
31. LBP-019 Safety and antiviral activity of AHB-137, a novel antisense oligonucleotide, in healthy volunteers and subjects with chronic hepatitis B
32. LBP-037 Role of early on-treatment serum hepatitis B virus RNA declines in the prediction of hepatocellular carcinoma risk in patients with chronic hepatitis B
33. OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
34. LBP-043 A phase 1, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of AHB-137 in Chinese healthy volunteers and subjects with chronic hepatitis B
35. China Registry of Hepatitis B (CR-HepB) : Protocol and implementation of a nationwide hospital-based registry of hepatitis B
36. Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients
37. Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis
38. Detachable string magnetically controlled capsule endoscopy for detecting high-risk varices in compensated advanced chronic liver disease (CHESS1801): A prospective multicenter study
39. Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts
40. Deep Convolutional Neural Network-Aided Detection of Portal Hypertension in Patients With Cirrhosis
41. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
42. Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)
43. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement
44. Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy
45. CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+ T cells favors viral control in chronic HBV infection
46. Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients
47. Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
48. A genetic variant of CXCR4 predicts pegylated interferon-alpha treatment response in HBeAg-positive chronic hepatitis B patients
49. Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients : The GIANT-B Study
50. Longitudinal Change of Body Mass Index Is Associated With Alanine Aminotransferase Elevation After Complete Viral Suppression in Chronic Hepatitis B Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.